Glenmark Farmacêutica, has entered into an exclusive partnership agreement with Novartis to distribute latter’s three respiratory products in Brazil.
Under the terms of the agreement, Novartis remains the holder of the registration of these medicines and will be responsible to manufacture them, Glenmark will be responsible for promoting, commercializing and distributing of these products in Brazil.
This agreement will be effective from July 1, 2019 onwards.
The products involved in the agreement are Seebri (Glycopyrronium bromide), Onbrize (Indacaterol) and Ultibro (combination of Indacaterol and Glycopyrronium), which are indicated towards treatment of the symptoms of chronic obstructive pulmonary disease (COPD) in adults.
This deal will ensure Glenmark to bolster the presence in Brazil market with advance respiratory portfolio. Indeed US market is getting tougher for all generic and non-US companies. Day by day